Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 17 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

35%

6 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(50.0%)
Phase 2
3(30.0%)
Phase 1
1(10.0%)
Phase 3
1(10.0%)
10Total
Phase 4(5)
Phase 2(3)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials
NCT00951782Phase 2Completed

Deep High-Frequency Repetitive Transcranial Magnetic Stimulation for Smoking Cessation

Role: lead

NCT01154712Phase 1Unknown

Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling

Role: lead

NCT00564096Phase 2Unknown

Transcranial Magnetic Stimulation (TMS) in Schizophrenia

Role: lead

NCT00577070Phase 2Completed

Evaluation of the H-Coil Transcranial Magnetic Stimulation(TMS) Device- Augmentation for Drug Resistant Depression

Role: lead

NCT00845936Phase 4Unknown

Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics

Role: lead

NCT00456937Phase 4Completed

Escitalopram in Schizophrenia in OCD- Open Label Study

Role: lead

NCT00465283Phase 4Unknown

Donepezil Double Blind Trial for ECT Memory Disfunction

Role: lead

NCT00687089Completed

Examination of Cognitive Function in Patients Treated With Subutex

Role: lead

NCT00708396Phase 4Unknown

Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study

Role: lead

NCT00797329Unknown

Biological and Cognitive Markers of Violent Behavior in Forensic Patients With Polysubstance Use: Retrospective Evaluation

Role: lead

NCT00789906Unknown

Development of Population Norms of the Computerized Neuropsychological Assessment for Effectiveness of the Antipsychotic Treatment in Schizophrenia

Role: lead

NCT00729820Unknown

The Influence of Personality on Two Aspects of Cognitive Performance: Processing Speed, and Accuracy.

Role: lead

NCT00659919Phase 4Completed

Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

Role: lead

NCT00524979Completed

Digital Voice Analysis in Patients With Schizophrenia

Role: lead

NCT00531830Unknown

Assessment of Factors Which Predict Improvement in Children With PDD After a Year of Integrative Therapy

Role: lead

NCT00531648Unknown

Relationships Between Toddlers With Feeding Disorder and SPD and Their Parents

Role: lead

NCT00148447Phase 3Completed

The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia

Role: lead

All 17 trials loaded